Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Propanc Biopharma said its PRP candidate produced more than 90% mean tumor growth inhibition in pancreatic cancer models. The release also compared the preclinical data with Revolution Medicines' recently approved daraxonrasib.
Propanc Biopharma said its preclinical PRP package showed 90% tumor growth inhibition and more than 2.5-fold survival extension in advanced PDAC models.
Propanc Biopharma (PPCB) says its PRP produced 90% tumor growth inhibition in pancreatic cancer models, contrasting its profile with Revolution Medicines’ daraxonrasib.